Caroline Loewy is an accomplished biopharmaceutical and financial executive with over 25 years of experience in the field. She currently provides strategic advisory services for development-stage biopharmaceutical companies focusing on product pipeline evaluation, funding strategies, and business development. Caroline has held the position of CFO for biopharmaceutical companies, successfully raising over $300 million in capital. Prior to her roles in company management, Caroline spent 11 years as a senior biotechnology equity research analyst at Morgan Stanley and Prudential Securities. She was recognized by the Wall Street Journal and Institutional Investor for her ability to identify promising biotechnology companies and raised over $4 billion. Caroline has leveraged her experience in the medical arena and financial expertise to benefit those affected with rare disorders. She is a founding board member of Global Genes, and Treasurer of the KCNQ2 Cure Alliance Foundation.